{"id":7402,"date":"2005-04-18T09:15:24","date_gmt":"2005-04-18T08:15:24","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=7402"},"modified":"2014-05-21T18:40:41","modified_gmt":"2014-05-21T18:40:41","slug":"pegasys-approved-for-hivhepatitis-c-coinfection-in-europe-and-us","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/7402","title":{"rendered":"Pegasys approved for HIV\/hepatitis C coinfection in Europe and US"},"content":{"rendered":"<p><strong>In February, PegInterferon (Pegysys, Roche) was approved for treatment for hepatitis C in clincally stable patients that are coinfected with HIV. The European and US decision came within a few weeks of each other.<\/strong><\/p>\n<p>Approval was based on results on the APRICOT study, reported last year in full in NEJM. [1]<\/p>\n<p>Source: Roche press release.<br \/>\n<a href=\"http:\/\/www.roche.com\">http:\/\/www.roche.com<\/a><\/p>\n<p>Reference:<\/p>\n<ol>\n<li>Torriani FJ et al. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis c Virus Infection in HIV-Infected Patients. N Engl. J Med. 2204;351(5): 438-450.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>In February, PegInterferon (Pegysys, Roche) was approved for treatment for hepatitis C in clincally stable patients that are coinfected with HIV. The European and US decision came within a few weeks of each other. Approval was based on results on &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-7402","post","type-post","status-publish","format-standard","hentry","category-hepatitis-coinfection"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=7402"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7402\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=7402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=7402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=7402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}